期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

维拉帕米对心肌缺血再灌注损伤状况下血浆内皮素水平的影响 被引量：1

THE INFLUENCE OF VERAPAMIL ON PLAMSA EDOTHELIN ON THE MODEL OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
下载PDF
导出
摘要 目的　观察维拉帕米对心肌缺血再灌注损伤后血浆内皮素 (ET)水平的影响 ,探讨其心肌保护作用的可能机制。方法　根据心肌缺血再灌注的不同时限对 30只家兔进行分组 ,建立家兔心肌缺血再灌注模型 ,采用放免法检测同一剂量维拉帕米 (0 .2mg/kg静脉注射 )对缺血再灌注不同时限血浆ET水平。结果　与生理盐水组比较 ,维拉帕米能降低血浆ET水平 (P <0 .0 5 )。 Objective To investigate the mechanism of the myocardial protection of Verapamil on myocardial ischemia reperfusion injuiy in rabbits by oberserving plasma edothelin. Methods The model of myocardial ischemia reperfusion in rabbits were established ,30 rabbits were divided into groups according to the different time of reperfusion and whether Verapamil (0.2mg/kg ,i.v) were used or not ,and plamas edothelin(ET) were measured by radioimmunosasay method. Results Compared with the NS groups,Verapamil can significantly reduce the concentrations of plasma ET (P<0.05) Conclusion The myocardial protection of Verapamil may be realized by reducing the plasma concentrations of ET.
作者 王嵘 苏晓灵 周白丽 龙启福
机构地区 青海医学院生化教研室 青海省人民医院心内科
出处 《青海医学院学报》 CAS 2004年第2期77-78,共2页 Journal of Qinghai Medical College
关键词 维拉帕米 心肌缺血再灌注损伤 ET Verapamil Myocardial Ischemia Reperfusion Injury ET
分类号 R542.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献5

  • 1余颂涛,阎敬初.内皮素——一种新的强效血管收缩肽[J].心血管病学进展,1991,12(4):208-211. 被引量：5
  • 2胡萍 尤家碌 等.大白鼠心脏再灌流综合征模型[J].湖南医学院学报,1986,11(1):15-17.
  • 3Yanagizawa M,Kurihara H,Kimura S,et al.A novel potent constrictor peptide produced by vasothelial cells. J Nature, 1988,332(6163) :411
  • 4Pemow J, Q - D Wang. Endothelin in myocardial ischemia and reperfuxion. Cardiovasc Res 1997,33(3 ) :518 - 526
  • 5邱志兵.内皮素与心肌缺血再灌注损伤[J].国外医学（老年医学分册）,2001,22(4):158-161. 被引量：11

二级参考文献11

  • 1[1]T ф nnessen T, Giaid A, Saleh D et al. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res, 1995;76:767～772
  • 2[2]Pernow J, Q-D Wang. Endothline in myocardial ischaemia and reperfusion. Cardiovasc Res, 1997;33:518～526
  • 3[3]Dvenport AP, O Reilly G, Kuc RE. Endothelin ET(a) and ET(b) mRNA and receptors expressed by smooth muscle in the human vasculature:majority of the ET(a) subtype. Br J Pharmacol, 1995;114:1110～1116
  • 4[4]Natarajan S, Hunt JT, Festin S et al. Endothelin analogs which distinguish vasodilator ETB receptors. Life Sci, 1995;56:1251
  • 5[5]Watanabe TA, Wane Y, Ikeda S et al. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-004 and the inhibition of myocardial infarct size in rats. Br J Pharmacol, 1995;114:949～954
  • 6[6]Hasdai D, Kornowski R, Battler A. Endothelin and myocardial ischemia. Cardiovasc Drug Ther, 1994;8:589～599
  • 7[7]Illing B, Horn M, Han H et al. Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical fcmetion and energy metabolism during ischemiafrefnsion injury in; solated perfused rat hearts, J Cardiovasc Pharmacol, 1996;27(4):487～494
  • 8[8]Wang QD, Li XS, Lundberg JM et al. Protectine effects of non-peptide endothelin recepter antagonist bosentan on myocardial ischemic and reperfusion injury in the pig. Cardiorasc Res,1995; 29(6):805～812
  • 9[9]Gonon AT, Wang QD, Shimizu M et al. The novel non-peptide selective endothelin A receptor antagonist LU135.252 protects against myocardio ischemic and reperfusion injury in the pig. Acta Physiol Scand, 1998;163(2):131～137
  • 10[10]Brunner F, Kukoretz WR. Postischemic antiarrhythmiz effects of angiotensin converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Circulation, 1996;94(7):1752～1761

共引文献15

同被引文献6

引证文献1

青海医学院学报
2004年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部